LONDON, May 7, 2013 /PRNewswire/ --
A new report by visiongain predicts the world rheumatoid arthritis (RA) drug market will generate revenue of $38.5bn in 2017. That forecast and others appear in Rheumatoid Arthritis (RA): World Drug Market 2013-2023, published in April 2013. Visiongain is a business information provider based in London, UK.
According to visiongain's new study, the overall market for RA drugs will expand during the first half of the forecast period, although with declining annual growth. That revenue expansion is limited by the patent expiry of the leading NSAID, Celebrex, as well as increasing competition and market saturation. Also, the world RA medicines market will have negative growth from 2018 to 2023, as a result of patent expiry of the leading biologic drugs and competition from biosimilars (follow-on biologics).
Jennifer Taylor, a pharmaceutical industry analyst in visiongain, said: "The strengths of the RA drug market stem from the high profile of the disease, which requires long term drug treatment, generating high volumes of sales. Also, variability in response rates among patients means that the market can support a high number of products. The market will also be supported by a well stocked R&D pipeline. However, patent protection for many of the leading biologic drugs is expected to expire during our forecast period. Changes in legislation around the world, including the US, mean that biosimilars will be approved for marketing. Competition from biosimilars poses a threat to this sector, especially as revenue from biologic drugs currently forms 87.5% of the total RA drug market."
Visiongain's report shows revenue forecasts to 2023 at world market, submarket, product and national level. It forecasts these world-level submarkets:
- Biologics (biological drugs)
For the non-biologics submarket, there are further revenue breakdowns to 2023:
- Conventional DMARDs
- Others agents (grouped, including novel DMARDs and corticosteroids).
That investigation also predicts revenues of leading brands in the rheumatoid arthritis drugs market, including Celebrex, Arcoxia, Remicade, Humira and Enbrel. Research, data and analyses cover activities of Abbott Laboratories (AbbVie), Roche, Pfizer, Johnson & Johnson, Amgen and other pharmaceutical companies.
That new study also discusses R&D and commercial developments, shows research interviews and predicts overall revenues to 2023 in leading national markets. The work analyses the US, Japan, Germany, France, the UK, Spain, Italy (EU5), Brazil, Russia, India and China (BRIC countries).
Rheumatoid Arthritis (RA): World Drug Market 2013-2023 therefore adds to visiongain's range of analytical reports on industries and markets in healthcare.
For sample pages and further information concerning the visiongain report Rheumatoid Arthritis (RA) The world drug Market 2013-2023 please visit
For an executive summary please contact:
Email: Sara Peerun on email@example.com
Tel: +44 (0) 20 7336 6100
Abbott Laboratories (AbbVie)
Baylor Research Institute
Centers for Disease Control and Prevention
Centocor Ortho Biotech
Dr. Reddy's Laboratories
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Hospital for Joint Diseases and Medicine
Janssen Scientific Affairs
Johnson & Johnson
Jyväskylä Central Hospital
Korean Food and Drug Administration (KFDA)
Merck & Co.
National Institute for Health and Clinical Excellence (NICE)
New York University
The Hospital for Special Surgery
The World Health Organization (WHO)
Notes for Editors
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Automotive and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44-(0)207-336-6100